Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ADK | P55263 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7990561 | 0.89 | LMNA (0.68) | SLC29A1HIF1AADKALDH1A1LMNA | |
| SCHEMBL18486402 | 0.86 | ADK (0.54) | SLC29A1HIF1AADK | |
| SCHEMBL21874996 | 0.82 | SLC29A1 (0.67) | SLC29A1 | |
| SCHEMBL19699262 | 0.81 | DNPH1 (0.59) | SLC29A1 | |
| SCHEMBL23982158 | 0.81 | SLC29A1 (0.76) | SLC29A1HIF1ASMN1; SMN2 | |
| SCHEMBL2288114 | 0.81 | SLC29A1 (0.76) | SLC29A1HIF1ASMN1; SMN2 | |
| SCHEMBL21011278 | 0.81 | SLC29A1 (0.76) | SLC29A1HIF1ASMN1; SMN2 | |
| SCHEMBL14873532 | 0.81 | SLC29A1 (0.76) | SLC29A1HIF1ASMN1; SMN2 | |
| SCHEMBL27183207 | 0.81 | SLC29A1 (0.76) | SLC29A1HIF1ASMN1; SMN2 | |
| SCHEMBL23982135 | 0.81 | SLC29A1 (0.76) | SLC29A1HIF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | SLC29A1 243/4885HIF1A 869/4885ADK 2823/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | SLC29A1 253/4885HIF1A 885/4885ADK 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.